Pay in 4 interest-free payments of $25.00 Learn more
Ships within 48 hours · Estimated delivery Oct 17 - Oct 22
K 03861 is able to override drug resistance that less potent "type I" inhibitors and "type II" first-generation FLT3 inhibitors cannot
CAS Number: 4999-79-5
SAR131675 is the first highly specific VEGFR-3-TK inhibitor described to date
K Likhitwitayawuid
Glycosaminoglycans modulate inflammation and apoptosis in LPS-treated chondrocytes
BGB-283 ide Rb3 K 03861 is able toBGB 283 is a novel and potent Raf Kinase and EGFR inhibitor with IC50 values of 23 and 29 nM for recombinant BRafV600E and EGFR, respectively. BGB 283 potently inhibits BRafV600E activated ERK phosphorylation and cell proliferation. It demonstrates selective cytotoxicity and preferentially inhibits proliferation of cancer cells harboring BRafV600E and EGFR mutation amplification. In BRafV600E colorectal cancer cell lines, BGB 283 effectively inhibits
US$ 143.37
US$ 560.00
US$ 1259.82
US$ 700.00
US$ 624.50
US$ 2501.46